1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
10.86%
Cash & equivalents growing 10.86% while Drug Manufacturers - Specialty & Generic shows decline of -14.22%. Warren Buffett would see this as a competitive advantage in maintaining liquidity while peers face cash constraints.
-28.40%
Short-term investments yoy growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -4.21%. Joel Greenblatt might see stronger near-cash accumulation as an opportunity. Check yields vs. peers.
3.20%
Below half the Drug Manufacturers - Specialty & Generic median of -12.12% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
17.53%
Receivables growth is below half the Drug Manufacturers - Specialty & Generic median of -29.12% (much lower). Joel Greenblatt would investigate if this reflects stronger collection discipline.
2.84%
Inventory growth less than half of Drug Manufacturers - Specialty & Generic median of 8.38%. Joel Greenblatt might see well-managed stock levels if revenue is fine.
-43.90%
Other current assets growth less than half of Drug Manufacturers - Specialty & Generic median of 21.83%. Joel Greenblatt would see a leaner short-term structure vs. peers.
0.34%
Below half the Drug Manufacturers - Specialty & Generic median of -13.04%. Jim Chanos would question if the company faces working capital strain.
3376.00%
PP&E growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 4.68%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
-42.12%
Goodwill growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for future write-down risk or pricey takeovers.
-97.47%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -29.41%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-63.96%
Below half of Drug Manufacturers - Specialty & Generic median of 159.16%. Joel Greenblatt sees relatively minimal intangible expansions vs. peers.
0.97%
Below half Drug Manufacturers - Specialty & Generic median of -6.96%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
No Data
No Data available this quarter, please select a different quarter.
-97.96%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -18.12%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
-49.00%
Below half the Drug Manufacturers - Specialty & Generic median of 20.97%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
-39.05%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -1.55%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
8.53%
Payables growth below half of Drug Manufacturers - Specialty & Generic median of -9.14%. Joel Greenblatt sees more conservative payables management vs. peers.
-7.17%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
16.23%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
No Data
No Data available this quarter, please select a different quarter.
-87.36%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -38.73%. Jim Chanos suspects a potential short-term burden spike.
6.91%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 3.90%. Jim Chanos suspects potential working capital strain.
-7.32%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
-96.98%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -22.24%. Jim Chanos suspects major expansions in deferred taxes.
-32.73%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -15.46%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-30.63%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -16.97%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
-16.59%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -1.00%. Jim Chanos suspects an alarming rise in overall leverage.
7.07%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-35.61%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of -3.72%. Joel Greenblatt sees stronger retained profit growth vs. peers.
18.65%
Above 1.5x Drug Manufacturers - Specialty & Generic median 9.65%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
-44.63%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of -1.69%. Joel Greenblatt sees stronger equity growth vs. peers.
-39.05%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of -1.55%. Joel Greenblatt sees more aggressive expansions than peers.
-23.36%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of -5.71%. Joel Greenblatt sees bigger push into investments vs. peers.
-4.41%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-25.62%
Below half of Drug Manufacturers - Specialty & Generic median 15.14%. Joel Greenblatt sees stronger deleveraging or cash accumulation vs. peers.
